The content on this site is intended for healthcare professionals only
Dr Walker speaks with ecancertv at ESMO 2016 about the analytical consistency of four PDL-1 assays.
She describes results based on assaying samples from head and neck cancers, with three of four assays being tested reaching a high degree of result harmonisation.
Dr Marianne Ratcliffe spoke with ecancertv earlier in the year at AACR 2016 about PDL-1 assay concordance, and Dr Walker considers the advances on the data presented then, and wider adoption of immuno-oncology in the future.
PD-1 and PDL-1 expression was considered in multiple sites during ESMO 2016, including prostate cancer by Dr Julie Graff, melanoma by Dr Alexander Eggermont and lung cancer by Dr Martin Reck.
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
SABCS 2025: Latest developments in multigene testing in early breast cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
Tele-mentoring: Impact of project ECHO
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma in a resource constrained setting
Choosing Wisely in radiology Tanzania
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
